title: Human cytomegalovirus-based immunotherapy to treat glioblastoma: Into the future.
abstract: Glioblastoma multiforme (GBM) is the most aggressive brain tumor and median survival time with current therapies is only 14.6 mo. Although multiple immunotherapeutic strategies are being explored, efficacy remains poor. In order to improve immunotherapy for GBM, we propose to combine currently used endogenous with human cytomegalovirus (HCMV) specific antigens expressed on cancer cells.
authors.affiliation: Department of Molecular Cell Biology and Immunology, VUmc , Amsterdam, the Netherlands.
authors.forename: Sanne
authors.initials: S
authors.lastname: Duinkerken
authors.affiliation: Department of Molecular Cell Biology and Immunology, VUmc , Amsterdam, the Netherlands.
authors.forename: Yvette
authors.initials: Y
authors.lastname: van Kooyk
authors.affiliation: Department of Molecular Cell Biology and Immunology, VUmc , Amsterdam, the Netherlands.
authors.forename: Juan J
authors.initials: JJ
authors.lastname: Garcia-Vallejo
keywords: C-type lectin receptor; HCMV; dendritic cell; glioblastoma; immunotherapy; vaccination